Tropical Biosciences is a gene-editing firm which develops high-performing commercial varieties of tropical crops which promote cultivation efficiencies, enhance consumer health, and improve sustainable environmental practices.
Tropic is focused on developing solutions for tropical regions, which are among the world’s leading ag producers – but also most affected by problems of poverty and climate change.
Tropic Biosciences was founded in 2016 by Eyal Maori, Ofir Meir, and Gilad Gershon. The company is headquartered in Norwich, Norfolk, UK.
Tropic Biosciences is applying gene-editing techniques to “promote cultivation efficiencies, enhance consumer health, and improve sustainable environmental practices” in tropical agriculture. The company is focusing on creating high-performance varieties of three key tropical commodity crops: banana, coffee, and rice.
Tropic Biosciences uses its GEiGS gene-editing tool to test them in the field to determine their resistance to Panama disease. The GEiGS gene-editing technology also has the potential to create disease- and pest-resilient row crops such as soybeans, corn and wheat.
Tropic is backed by Temasek, Blue Horizon, Tekfen Ventures, Sumitomo Corporation Europe, Genoa Ventures, Emerald Technology Ventures, DisruptAD, Agronomics, Skyviews Life Science, Bloom8, Sucden Ventures, and others. The company raised $35M in new financing on Jul 06, 2022. This brings Tropic's total funding to $73.5M to date.